ESR1 and breast cancer: Breast tumors of the luminal subtype expressing Estrogen Receptor alpha (ERα) represent a prominent part of breast cancers and are treated with anti-estrogenic drugs with good rate of success, albeit endocrine resistance is still difficult to detect and justifies failure in one-fourth of cases [1].